Business Wire

Regula Helps Austrian Municipalities Facilitate ID Verification and Processing

Share

Municipal registration offices across Austria have integrated advanced document readers Regula 7024M to automate and secure identity verification processes. This initiative is part of the “Sicheres Meldeamt” (secure registration office) project, launched by the Federal Ministry of Internal Affairs of Austria.

In Austria, the municipal registration office (Meldeamt) plays a crucial role in the administrative process for both citizens and residents. It's where individuals are required to register their place of residence, which is an essential part of living in Austria. However, its role extends beyond mere registration; it facilitates a smooth transition for individuals moving within or to Austria, granting them access to public services and contributing to orderly municipal management.

The need for modernization

Traditionally, the verification of identity documents in Austrian registration offices has been based predominantly on manual work, which requires a certain level of expertise, is time-consuming and prone to errors. Recognizing the need for more efficient and hurdle-free operations, theMinistry of Internal Affairs has launched the “Sicheres Meldeamt” initiative and has offered registration offices a new approach to automate identity document reading and verification.

The solution

To realize the “Sicheres Meldeamt” project across the whole country, cooperation with IT service providers to Austrian registration offices was initiated. Among these providers are Kufgem, Gemdat OÖ, PSC, Comm-Unity EDV, Gemdat NÖ, and others. They have offered to equip registration offices with compact desktop document readers Regula 7024M.

Regula’s devices were chosen because they feature advanced OCR technology tailored for identity documents, MRZ and barcode reading modules, and multiple light sources. It helps Regula 7024M accurately identify various data types, including engraved and embossed text. Additionally, the device comes equipped with an RFID chip reading module to enable the verification of biometric documents. By performing extensive data cross-checks, Regula 7024M helps identify any possible inconsistencies in personal information that may indicate fraud.

First results and future prospects

The pilot projects in cities like Linz, Telfs, and Sankt Pölten have shown significant improvements in the registration processes. With Regula 7024M, documents are processed instantaneously, significantly reducing the manual workload and virtually eliminating human error.

Christoph Heichinger, Ministerial Councillor from the Central Office of the Federal Ministry of Internal Affairs of Austria and one of the project managers of the “Sicheres Meldeamt” project, stated, "The digital enhancement of the registration process allows registration offices to create effective protection mechanisms against the unauthorized use of registration confirmations. This is achieved by using high-quality passport and document readers for verifying documents."

Now, the “Sicheres Meldeamt” project is going to be extended to other registration offices in Austria.

“We are immensely proud to see our document readers streamlining and securing ID processing in Austrian registration offices. Regula 7024M is a powerful tool capable of transforming the daily operations of border controls and immigration services. This initiative sets a new nationwide benchmark for identity verification and we look forward to continuing our support for the ‘Sicheres Meldeamt’ project as it expands across the country,” said Maris Kaminskis, Executive Director at Regula Europe.

To learn more about Regula’s involvement in the “Sicheres Meldeamt” project, please read the success story.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909830261/en/

Contacts

Kristina – ks@regulaforensics.com

Kristina – ks@regulaforensics.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye